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A B S T R A C T
The knowledge that the persistent infection with high-risk (HR) human papillomavirus (HPV) is the etiological factor
in the development of cervical cancer has led to the development of the HPV DNA detection methods as well as the pro-
phylactic vaccine against the most common HR-HPV types, HPV 16 and 18. Despite HPV vaccination, cervical cancer
screening will remain the main preventive measure for both vaccinated and non-vaccinated women, but the nature of
screening and management of women with cervical disease is being adapted to the new technologies. Although, HPV
DNA detection is more sensitive that cytology, its specificity is lower, since most HPV infections are transient. Therefore,
other methods are considered to improve the management of women with cervical disease. Typing of HPV DNA and viral
load measurements are still used for research purposes only. Detection of viral oncogene E6/E7 transcripts, which is the
marker of the productive infection, is a promising tool for follow-up of HPV DNA-positive women. The detection of
p16INK4a over-expression, as an indirect test of E6/E7 expression, is used for confirmation of cervical neoplasia. Despite
the lack of standardization, the detection of p16INK4a is useful in clinical settings, however its reproducibility in the
management of low-grade and borderline cases is low. Future perspectives include the determination of the methylation
status of several cellular genes that could predict the progression of the disease.
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Introduction
The causal relationship between the persistent infec-
tion with carcinogenic or high-risk (HR) human papillo-
mavirus (HPV) and cervical cancer is now well esta-
blished1,2. Prophylactic vaccination against the most
common causes of cervical cancer, HPV types 16 and 18
accounting for 70–75% of cervical cancer cases, is avail-
able since several years ago3. However, not all cervical
cancer cases could be prevented by vaccination, so
screening for cervical cancer remains the main measure
of prevention for both vaccinated and non-vaccinated
women.
As it takes several decades for cervical changes to de-
velop from atypical, low, mild and high abnormalities to
invasive cancer, there is enough time for early detection
of precancerous lesions. Therefore, cervical cytology (Pa-
panicolaou or Pap smear) was, and still is, the test of
choice for detection of cervical precancerous lesions,
since its introduction in the early 1960s4.
The conventional cytology by Pap smear is easy to
perform and it is a relatively low-cost screening test.
However, Pap test is highly subjective. The sensitivity
and specificity varies between laboratories, from 11 to
99%, and 14 to 97%, respectively5. In addition, the need
to often repeat the test because of the high prevalence of
unsatisfactory and false negative results undermines test
cost-effectiveness. Therefore, test accuracy and its cost-
-effectiveness highly depend on the quality control of its
performance6. The liquid based cytology (LBC), despite
having several advantages, has similar sensitivity and
specificity for detecting high-grade cervical intraepithe-
lial neoplasia (CIN2+) compared to conventional cyto-
logy7–9. LBC is less time consuming, reduces the number
of unsatisfactory cervical smears and allows residual
sample to be used for additional testing. In addition, LBC
can be automated, allowing large number of samples to
be processed per day.
Nowadays, several tests complementing the Pap test
are being evaluated in clinical settings. This review fo-
cuses on challenges in cervical cancer early detection and
control using new technologies, such as HPV testing
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based either on viral DNA or RNA analysis, detection of
the molecular biomarker p16INK4a, and evaluation of
DNA methylation status.
DNA Based HPV Testing
Recognition that cervical cancer is causally linked to
HR-HPV types led to the use of HPV DNA testing. HPV
DNA tests are based on detection of DNA of at least 13
carcinogenic HPV types (HPV 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59 and 66)2, either by DNA amplification
(polymerase chain reaction-PCR) with type-specific pri-
mers or by hybridisation with a cocktail of probes10. Tho-
se tests are more sensitive, objective, reproducible, and
less demanding, in terms of training and quality assur-
ance, compared to cytology. In addition, there are a few
commercially available, EMEA (European Agency for the
Evaluation of Medical Products) and FDA (Food and
Drug Administration of the United States) approved
HPV DNA assays, of which the Hybrid Capture 2 (HC2,
Qiagen GmbH, Hilden, Germany) is widely used in clini-
cal laboratories. HPV DNA testing with HC2 showed to
be very useful for triage of equivocal cytology samples
(ASC-US, atypical squamous cells of undetermined sig-
nificance), and for follow-up of women after treatment
for high-grade cervical disease.
Several studies and meta-analyses have demonstra-
ted that HPV DNA testing is highly effective for the tri-
age of women having ASC-US. It is more sensitive and
equally specific as cytology in identifying women with
underlying clinically relevant cervical disease (CIN)11,12.
Cuzick et al.12 determined that the HC2 assay for triage
of women with ASC-US has an overall sensitivity of
93.1% (95% CI: 91.1–95.1%) and 95.5% (95% CI: 92.7–
98.2%), and specificity of 62.3% (95% CI: 57.6–67.1%)
and 60.5% (52.9–68.2%) for detecting CIN2+ and
CIN3+, respectively. For triage of women with LSIL
(low-grade squamous intraepithelial lesions) the sensi-
tivity of HC2 was also very high, 97.2% (95% CI: 95.6–
98.8%) for detecting CIN2+ and 97.1% (95% CI: 94.0–
100%) for detecting CIN3+ but the specificity was very
low, 30.6% (95% CI: 22.7–38.6%) for detecting CIN2+
and 26.1% (95% CI: 15.1–37.1%) for detecting CIN3+.
However, for women aged 35 or more, the HPV positivity
rate was much lower than for younger women and the
potential value of HPV DNA testing as an adjunct to cy-
tology in this group was substantially better than for
younger women12,13.
Comparison of the accuracy of HPV DNA testing for
the triage of ASC-US or worse with cytology showed that
the sensitivity of HC2 was on average 14% higher than
repeat cytology for detection of CIN2+ (ratio: 1.14; 95%
CI: 1.08–1.20) and has similar specificity (ratio: 0.99;
95% CI: 0.88–1.10)12. The Croatian study, Pajtler et al.14
using PCR method to estimate the predictive value of
HPV testing for disease prognosis, emphasises the need
to carefully evaluate the value of HPV testing in a rou-
tine practice.
Studies concerning post-treatment follow-up, although
heterogeneous, indicate that HPV DNA testing perfor-
med better than follow-up by cytology to predict success
or failure of treatment. It has significantly higher sensi-
tivity and its specificity is not significantly lower com-
pared to cytology10. Based on these convincing data, ap-
plication of HPV DNA testing has been recommended in
the European Guidelines on Quality Control in Cervical
Cancer Screening15 and has been introduced into routine
practice in many countries, including Croatia9,14,16.
HPV DNA testing for primary screening, with cytol-
ogy reserved for triage of HPV positive women, has been
evaluated in several randomised controlled studies as a
sole test or in combination with cytology17. All these
studies suggest that HPV DNA testing is more sensitive
than cytology in primary cervical screening in women
over the age of 30. HPV DNA testing was substantially
more sensitive in detecting CIN2+ lesions than conven-
tional cytology (96% vs. 53%) but was less specific (91%
vs. 96%). However, the specificity of both tests increased
with age. The sensitivity of HPV DNA testing was uni-
formly high at all ages, whereas the sensitivity of cytol-
ogy was substantially better in women over the age of 50
than in younger women (79% vs. 60%). The biggest ad-
vantage of HPV DNA testing in primary screening is its
negative-predictive value (NPV) that guarantees safe ex-
tension of the interval for re-screening of HPV negative
women to 5 or more years18.
In the Proposal for the programme of early detection
of cervical cancer in Croatia submitted in 2004 to the
Ministry of Health and Social Welfare19, HPV testing as
primary screening was suggested to be implemented af-
ter the first round of the programme. Actually, the prior-
ity is still to establish the nation-wide cervical screening
programme based on conventional cytology, which is a
prerogative for subsequent piloting of HPV testing as
primary screening in Croatia.
Higher sensitivity of HPV DNA testing over cytology
offers several advantages, including, most importantly,
the potential of reducing cervical cancer rates, while si-
multaneously reducing the number of lifetime screens
and increasing the efficiency of cervical screening partic-
ularly as the proportion of HPV vaccinated women in-
creases in the population. Other HPV DNA based tech-
niques, such as real-time PCR for assessing the viral load
and/or the physical state of the viral genome, and HPV
DNA typing of most common HR HPV types are also
valuable biological markers of disease progression. Cur-
rently, these tests are reserved for research purposes
only. In case of viral load measurement, there are no vali-
dated tests available for clinical use and, therefore, the
true clinical relevance of the viral load measurement has
not been properly evaluated. HPV DNA types can be de-
termined by either type-specific PCR, hybridisation of
the consensus-PCR amplicon with specific probes or re-
striction fragment length polymorphism of the consen-
sus-PCR amplicon10,20. In addition, there are commer-
cially available HPV DNA typing methods, of which the
INNO-LiPA HPV Genotyping assay (Innogenetics
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Group, Gent, Belgium) and Roche LBA (Molecular Sys-
tems, Pleasanton, California), both designed for the iden-
tification of all 13 HR HPV types and more [few probable
HR and many low-risk (LR) types], are the most widely
used21. The commercial tests are useful for epidemiologi-
cal studies, but not as a clinical tests, as they can be con-
fusing for both the clinicians and women. A recent study
on HPV frequency in Croatia, showed that five most
commonly found HPV types in cervical cancer, HPV 16,
18, 31, 33 and 45, were also the most frequent types
found in high grade cervical lesion, which confirms clini-
cal relevance of HPV DNA typing22,23.
RNA Based HPV Testing
While the sensitivity of HPV DNA testing is very high
for detecting high-grade squamous intraepithelial le-
sions (HSIL), its specificity is lower than cytology (dis-
cussed in the previous Chapter). As most HPV infections
are in fact transient and regress spontaneously2, this low
specificity of DNA testing means that many women will
needlessly be referred to colposcopy and treatment. The-
refore, to make HPV DNA testing more efficient, differ-
ent biological markers are being evaluated to identify the
lesions that will progress. One very promising marker is
the presence of the viral oncogene transcripts E6 and E7.
The role of HPV E6 and E7 oncogenes in cell im-
mortalization and transformation is reviewed in detail
by Munger and Howely24. Briefly, E6 and E7 proteins dis-
rupt normal cell cycle and cell death control. During the
viral life cycle transcription of oncogenes is tightly regu-
lated and the gene expression is low25. In addition, the
transcription of E6 and E7 oncogenes is ongoing only in
the deep layers of the epithelium, specifically in his-
tological low-grade lesions (CIN1)26. Even though those
lesions can be HPV DNA positive, they remain HPV
mRNA negative. However, in CIN2+ lesions, the regula-
tion of transcription is gone and a large amount of E6/E7
transcripts can be found throughout the epithelium and
can be detected in the samples taken for analysis26,27.
The PreTect HPV-Proofer assay (NorChip/BioMé-
rieux Inc., Klokkarstua, Hurum, Norway) enables the
detection and identification of E6/E7 transcripts of HPV
types 16, 18, 31, 33 and 4528, while APTIMA® HPV assay
(Gen-Probe Inc., San Diego, CA, USA) allows the detec-
tion of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66 and 68, but not the identification of each trans-
cript29. The number of HPV types covered by the respec-
tive commercially available assays represents an issue to
be considered. However, HPV RNA testing is a promising
tool for triage of HPV DNA-positive women, who, if they
are also RNA-positive, are at greater risk of disease pro-
gression.
In a recent large comparative study30, several DNA
and RNA based methods were assessed for the detection
of CIN2+. Non-genotyping DNA tests in that study had
sensitivity, specificity and positive predictive value (PPV)
close to 99+%, 25% and 35%, respectively. RNA based
methods in the same study had similar sensitivity but in-
creased specificity and PPV. For the PreTect HPV-Proofer
assay, sensitivity, specificity and PPV values were 73.6%
(95% CI: 67.8–78.8), 73.1% (95% CI: 69.5–76.4) and 52.0%
(95% CI: 46.8–57.2), respectively. The APTIMA assay
had a sensitivity of 95.2% (95% CI: 92.0– 97.4) and again
both specificity and PPV were higher than DNA test val-
ues, 42.2% (95% CI: 38.4–46.0) and 39.9% (95% CI:
36.2–43.8), respectively30.
A study of Cuschieri et al.31 indicated that mRNA of
E6/E7 might also be a marker of persistence since 67% of
RNA-positive, and only 27% of RNA-negative samples
persisted for 2 years. Several issues need to be addressed
before clinical application of HPV RNA testing. The RNA
stability represents a major problem for the accuracy of
HPV RNA testing. Small scale studies have shown that
samples are well preserved in LBC medium even for sev-
eral weeks, but RNAse contamination and RNA degrada-
tion could be a problem32,33.
Detection of p16INK4a
HPV oncoproteins E6 and E7 act by deactivating tu-
mour suppressor genes p53 and pRB, respectively. It has
been proposed that inactivation of pRB in cells infected
with HR-HPV could lead to over-expression of cyclin-de-
pendent kinase inhibitor p16INK4a, which is negatively
regulated by pRb. This hypothesis has been confirmed
for HPV positive cervical cancer cell lines that showed
strong over-expression of p1634. Those findings promoted
the possibility of using immunostaining in the detection
of p16INK4a as an additional test for distinguishing be-
tween normal and neoplastic cervical epithelia.
Von Knebel Doeberitz group conducted a study on
histological samples, and tested several different anti-
bodies for detection of p16INK4a. Their results sup-
ported the hypothesis of over-expression of p16INK4a in
neoplastic cervical lesions. They also confirmed that
over-expression of p16INK4a is a good marker for cells
expressing viral E6/E7 oncoproteins35. The results of the
study by von Knebel Doeberitz group were the basis for
the development of a screening test for immunochemical
detection of p16INK4a over-expression, CINtec p16INK4a
Histology kit (mtm laboratories AG, Heidelberg, Ger-
many).
Klaes et al.36 have confirmed that the detection of
over-expression of p16INK4a can improve the interobser-
ver agreement in the histological diagnosis of cervical le-
sions in tissue sections. Immunostaining for p16INK4a
proved to be particularly helpful in distinguishing be-
tween CIN1 and CIN2+ lesions. They also found lack of
p16INK4a immunostaining in CIN1 lesions infected with
LR-HPV, compared to CIN1 lesions infected with HR-HPV36.
Results of this study showed that immunostaining for
p16INK4a also helped in focusing pathologist’s attention
to small clusters of dysplastic cells, and, therefore, im-
proved diagnosis in cases where the number of dysplastic
cells was low36.
Kanao et al.37 conducted a study to determine the lev-
els of mRNA for p16INK4a and the alternative transcript
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from the same gene locus, p14ARF in cervical cancer tis-
sues positive or negative for HPV infection to evaluate
possible correlation between p16INK4a/p14ARF over-ex-
pression and HPV infection. This study showed over-ex-
pression of p16INK4a/p14ARF only in HPV-positive can-
cer tissues, and suggested that HPV-negative cancers
might have the opposite mode of inactivation of p53 and
pRb, that involves inactivation of p16INK4a/p14ARF
gene. However, the study did not include sufficient num-
ber of HPV-negative cervical cancer samples to draw fi-
nal conclusions37.
In the study by Wang et al.38, patients with CIN1 le-
sions were followed-up for 5 to 7 years. The over-expres-
sion of p16INK4a could not be correlated with HPV sta-
tus, and was detected even in normal and inflammatory
epithelium, although in lower percentage of cases (12.5%
in normal epithelium, 75% in CIN and 75% in SCC).
However, they have noticed that cases positive for
p16INK4a developed cervical cancer in the shorter time
than those without over-expression of p16INK4a.
Wentzensen et al.39 investigated the methods for im-
proving the use of p16INK4a over-expression in LBC
screening, since it has been noticed that non-dysplastic
cells can also show increased expression of p16INK4a.
They tried to define morphologic criteria of the nuclei, to
enable scoring of p16INK4a-positive cervical cells, to
identify patients with HSIL.
Carrozi et al.40 tested the use of detection of p16INK4a
over-expression in conjunction to HPV testing. They
found p16INK4a over-expression in 88% (95% CI 80–94)
of HPV-positive specimens that were histologically con-
firmed CIN2 or worse. Therefore, they concluded that
p16INK4a staining is a useful tool to improve the speci-
ficity of HPV DNA testing, since it is strongly associated
with the CIN2+ lesions. In addition, the performance of
p16INK4a staining might be improved by using higher
cut-offs or nuclear scoring criteria in younger women,
where HPV infections are often transient40.
However, a recent meta-analysis that included 61 dif-
ferent studies showed that proven usefulness of the de-
tection of p16INK4a over-expression is undermined by
the lack of standardized methodology41. This problem is
more pronounced in p16INK4a cytology, since the his-
tological criteria for p16INK4a positivity are well de-
fined. Average proportion of p16-positive smears in cyto-
logical samples was 12% for normal, 45% for ASC-US,
45% LSIL and 89% for HSIL, and only 2% for normal,
38% CIN1, 68% CIN2, and 82% for CIN3 in histological
samples. The results of different studies were also very
heterogeneous, especially in the cytological samples gra-
ded as ASC-US (10–100% of p16 positive) and LSIL
(10–86% of p16 positive). The same problem was ob-
served for histological samples graded CIN1, where over-
-expression of p16 varied from 0–100% in different stud-
ies. The lack of reproducibility, that was especially high
in the assessment of low-grade lesions, invoked the con-
clusion that there is still not enough data to give recom-
mendations about the best use of p16INK4a detection in
clinical practice41.
Only a few studies evaluating the use of p16INK4a as
the adjunct to cytology was conducted in Croatia, so
far9,42,43. The authors of these studies all found that
p16INK4a was a useful adjunct to cytology. The results
obtained so far call for continuing efforts to try to deter-
mine the best use of p16INK4a as a marker of the pro-
gression of cervical lesions, since there are still too many
discrepancies emerging from different studies to be able
to use the method as a reliable test of disease progres-
sion, especially in low grade and borderline samples.
Future Perspectives: Evaluation of
DNA Methylation Status
The identification of specific biomarkers of early ma-
lignant progression would be useful to improve the selec-
tion of women with the increased risk of cervical disease.
Therefore, the appearance of epigenetic biomarkers in
relation to the stages of cervical carcinogenesis is consid-
ered as a promising diagnostic tool44.
It is well established that DNA methylation is a fre-
quent epigenetic event in many human cancers45,46. Over
the last decade, a growing number of studies evaluating
methylation status of host genes in cervical tissue have
been published45–50. A large number of cancer-related
genes are being recognized that harbour dense methy-
lation of cytosine in normally unmethylated CpG-rich se-
quences, called CpG islands, located within the 5’ gene
promoter regions51. Most of candidate biomarkers for
methylation analyzed in cervical tissues were previously
observed in other types of cancer50.
Nowadays, methylation assays are still being evalu-
ated. Although the majority of the studies uses methyla-
tion specific PCR (MSP) followed by Methylight, other
studies use quantitative MSP protocols, bisulfite sequen-
cing, and other methods (reviewed by Wentzensen et al.,
2009)50. Briefly, the MSP amplifies genomic DNA that is
modified by previous treatment with sodium bisulfite,
which converts all of the unmethylated cytosines to ura-
cil, whereas methylated cytosines remain unchanged.
Modified DNA is the template for PCR amplification
with specific primers for the methylated and unmethy-
lated forms of the gene49.
In the last decade, numerous studies analyzed me-
thylation status of various tumour suppressor genes (p16,
RAR, FHIT, GSTP1, MGMT, hMLH1, MAL, DAPK,
IGSF4, CDH1 and PAX1) and found that methylation
was a frequent event in CIN2+ lesions and tumour sam-
ples, very low in CIN1 samples and negative in control
samples from healthy women, suggesting that aberrant
methylation may indicate increased risk for cancer de-
velopment44,47–49. In 2009, Wentzensen et al. conducted a
systematic research on 51 published studies on the me-
thylation status of 68 genes in cervical tissues50. Among
15 genes analyzed in detail in those studies, 7 genes
(CDH1, FHIT, TERT, CDH13, MGMT, TIMP3 and HIC1)
showed very heterogeneous methylation frequencies in
cervical cancer. Only three markers, DAPK1, CADM1
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and RAR, showed elevated methylation in cervical can-
cers consistently across those studies.
There are no methylation markers that could be used
in cervical cancer screening, currently, however, tremen-
dous efforts to identify epigenetic biomarkers of progres-
sion of cervical disease are under way. In addition, the
methods for the evaluation of DNA methylation status
are still time consuming and cumbersome, and to be ap-
plicable in clinical practice they have to be well defined
and standardized. Therefore, early detection of cervical
cancer requires large scale well-powered epidemiologic
studies designed to properly identify, and then validate
methylation markers candidates.
Conclusion
Cytology screening complemented by HPV DNA and/
or RNA testing, and immunohistochemistry of p16INK4a
represents a powerful tool for management of women
with cervical precancerous lesions. Figure 1 summarizes
the possible clinical application of the new methods, de-
scribed in this review, for screening of the target popula-
tion of women and monitoring those with abnormal find-
ings for early detection of precancerous lesions. Detec-
tion of HR-HPV DNA is already widely used in clinical
practice. However, p16INK4a over-expression, and most
other DNA and RNA based methods require further
standardisation and extensive research. This is particu-
larly true for DNA methylation analysis, since several
methylation biomarkers were identified but none was
adapted and evaluated for clinical application, yet.
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screening and monitoring of cervical precancer and cancer.
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NOVE SPOZNAJE U KONTROLI RAKA VRATA MATERNICE I BUDU]E PERSPEKTIVE
S A @ E T A K
Saznanje da je trajna infekcija visokorizi~nim tipovima HPV-a uzrok nastanka raka vrata maternice dovelo je do
razvoja testova zasnovanih na detekciji DNA HPV-a te profilakti~kog cjepiva protiv dvaju naju~estalijih visokorizi~nih
tipova, HPV 16 i 18. Usprkos primjeni cjepiva, probir za rak vrata maternice ostaje glavni na~in prevencije i za `ene
koje su primile cjepivo i za one koje nisu cijepljene, ali je na~in probira i tretman `ena kod kojih su na|ene promjene
epitela prilago|en novim tehnologijama. Iako je detekcija DNA HPV-a puno osjetljivija od citologije, njena specifi~nost
je manja, jer su mnoge infekcije HPV-om prolazne. Zbog toga se razmatraju druge metode koje bi pobolj{ale pra}enje
oboljelih `ena. Tipizacija HPV-a i odre|ivanje koli~ine virusa za sad se koriste samo u istra`ivanjima i nemaju klini~ku
primjenu. Metoda detekcije transkripata virusnih onkogena E6 i E7, biljega produktivne infekcije, ~ini se obe}avaju}om
za pra}enje `ena koje su pozitivne na prisustvo DNA HPV-a. Metoda koja se ve} koristi u klini~kom okru`enju, premda
nije standardizirana, je detekcija pove}ane ekspresije p16INK4a, kao indirektni pokazatelj ekspresije virusnih onko-
gena. Tom metodom se potvr|uje prisustvo promjena cervikalnog epitela u citolo{kim i histolo{kim uzorcima. Usprkos
nedostatku standardizacije, metoda se pokazala korisnom kao dopuna klasi~nom citolo{kom i histolo{kom pregledu
uzoraka, ali je njena reproducibilnost kod `ena sa promjenama epitela niskog stupnja i grani~nim promjenama niska.
Metode koje se razmatraju i mo`da }e se koristiti u budu}nosti uklju~uju i odre|ivanje metilacijskog statusa nekoliko
stani~nih gena, iz ~ega bi se moglo predvidjeti kako }e bolest napredovati, ali one su jo{ uvijek u fazi istra`ivanja.
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